202466-68-0

Basic information

• Product Name: RO 04-6790
• Synonyms: 4-amino-n-[2,6-bis(methylamino)-4-pyrimidinyl]benzenesulfonamide dihydrobromide;4-Amino-N-[2,6-bis(methylamino)-4-pyrimidinyl]-benzenesulfonamide;BenzenesulfonaMide, 4-aMino-N-[2,6-bis(MethylaMino)-4-pyriMidinyl]-;4-amino-N-[2,6-bis(methylamino)pyrimidin-4-yl]benzenesulfonamide
• CAS NO: 202466-68-0
• Molecular Formula: C₁₂H₁₆N₆O₂S
• Molecular Weight: 381.2813
• Mol File: 202466-68-0.mol

Chemical Properties

• Boiling Point: 595.8°C at 760 mmHg
• Flash Point: 314.1°C
• Appearance: white/
• Density: 1.495
• Vapor Pressure: 3.69E-14mmHg at 25°C
• Storage Temp.: Store at -20°C
• Solubility: DMSO: >10mg/mL
• PKA: 9.16±0.50(Predicted)
• CAS DataBase Reference: RO 04-6790(CAS DataBase Reference)
• NIST Chemistry Reference: RO 04-6790(202466-68-0)
• EPA Substance Registry System: RO 04-6790(202466-68-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• RTECS: DA9462500
• Hazardous Substances Data: 202466-68-0(Hazardous Substances Data)

Usage

Uses

Ro 04-6790 is a SR-6 antagonist.

Biological Activity

Potent and selective 5-HT 6 receptor antagonist (pK i values are 7.26 and 7.35 at rat and human 5-HT 6 receptors respectively). Displays no affinity at a range of other receptors (IC 50 > 10 μ M). Induces stretching behavior in rats in vivo .

InChI:InChI=1/C12H16N6O2S.2ClH/c1-14-10-7-11(17-12(15-2)16-10)18-21(19,20)9-5-3-8(13)4-6-9;;/h3-7H,13H2,1-2H3,(H3,14,15,16,17,18);2*1H

Upstream product

• 122-11-2 sulfadimethoxine 
• 74-89-5 methylamine 

Relevant articles and documents

5-HT6 receptor antagonists: lead optimisation and biological evaluation of N-aryl and N-heteroaryl 4-amino-benzene sulfonamides

RO-04-6790 (6a) has been identified in a random screen for 5-HT6 receptor antagonists. In a medicinal chemistry optimisation program a series of analogs comprising N-heteroaryl- and N-arylbenzenesulfonamides have been synthesised and investigated for their binding affinity. Compounds with a log D profile indicative of brain penetration have been subjected to in vivo testing for reversal of a scopolamine-induced retention deficit in a passive avoidance paradigm.

USE OF SULFONAMIDES

The present invention is concerned with compounds of formula STR1 wherein Z is a substituted pyridyl group of formula STR2 R. sup.1 is hydrogen, amino, lower alkylamino, lower dialkylamino, lower alkyl, halogen, or trifluoromethyl;R 2 is hydrogen or lower alkyl;R 5 is hydrogen, lower alkyl, lower alkylamino, di-lower alkylamino, lower alkoxy, or halogen;R 6 lower alkylamino, di-lower alkylamino, lower alkoxy, halogen, or CF 3.